SUPERNUS PHARMACEUTICALS INC (SUPN)
US8684591089 - Common Stock
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Supernus Announces Third Quarter 2024 Financial Results
Supernus Announces Third Quarter 2024 Financial Results
Net sales of Qelbree® increased 68% in the third quarter of 2024, compared to the same period in 2023. Net sales of Qelbree of $62.4 million and $166.9...
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820 was...
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel,...
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
Ahead of ADHD Awareness Month, Busy is sharing her ADHD diagnosis and Qelbree® (viloxazine extended-release capsules) treatment story to empower women...
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
PDUFA Target Action Date of February 1, 2025 ROCKVILLE, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a...
Supernus Announces Second Quarter 2024 Financial Results
Supernus Announces Second Quarter 2024 Financial Results
Net sales of Qelbree® increased 92% in the second quarter of 2024, compared to the same period in 2023. $59.4 million and $104.5 million of net sales in...
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July.
Supernus Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for SUPN
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Supernus Pharmaceuticals Enters Oversold Territory (SUPN)
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to...